182 related articles for article (PubMed ID: 33381894)
1. Identification of biomarker panels as predictors of severity in coronary artery disease.
Ben Braiek A; Chahed H; Dumont F; Abdelhak F; Hichem D; Gamra H; Baudin B
J Cell Mol Med; 2021 Feb; 25(3):1518-1530. PubMed ID: 33381894
[TBL] [Abstract][Full Text] [Related]
2. Association of Plasma Matrix Metalloproteinase and Tissue Inhibitors of Matrix Metalloproteinase Levels With Adverse Treatment Outcomes Among Patients With Pulmonary Tuberculosis.
Kumar NP; Moideen K; Nancy A; Viswanathan V; Thiruvengadam K; Sivakumar S; Hissar S; Nair D; Banurekha VV; Kornfeld H; Babu S
JAMA Netw Open; 2020 Dec; 3(12):e2027754. PubMed ID: 33258908
[TBL] [Abstract][Full Text] [Related]
3. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease.
Tayebjee MH; Lip GY; Tan KT; Patel JV; Hughes EA; MacFadyen RJ
Am J Cardiol; 2005 Aug; 96(3):339-45. PubMed ID: 16054454
[TBL] [Abstract][Full Text] [Related]
4. Plasma metalloproteinase-12 and tissue inhibitor of metalloproteinase-1 levels and presence, severity, and outcome of coronary artery disease.
Jguirim-Souissi I; Jelassi A; Addad F; Hassine M; Najah M; Ben Hamda K; Maatouk F; Ben Farhat M; Bouslema A; Rouis M; Slimane MN
Am J Cardiol; 2007 Jul; 100(1):23-7. PubMed ID: 17599435
[TBL] [Abstract][Full Text] [Related]
5. [Clinical value of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 for the prediction and early diagnosis of coronary artery lesion in patients with Kawasaki disease].
Peng Q; Zhou TF; Chen CH; Hua YM; Liu HM; Hong H; Zhang LY; Wu Q
Zhonghua Er Ke Za Zhi; 2005 Sep; 43(9):676-80. PubMed ID: 16191301
[TBL] [Abstract][Full Text] [Related]
6. Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome.
Cheng M; Hashmi S; Mao X; Zeng QT
Can J Cardiol; 2008 May; 24(5):385-90. PubMed ID: 18464944
[TBL] [Abstract][Full Text] [Related]
7. Urinary levels of matrix metalloproteinase 9 and 2 and tissue inhibitor of matrix metalloproteinase in patients with coronary artery disease.
Fitzsimmons PJ; Forough R; Lawrence ME; Gantt DS; Rajab MH; Kim H; Weylie B; Spiekerman AM; Dehmer GJ
Atherosclerosis; 2007 Sep; 194(1):196-203. PubMed ID: 16942771
[TBL] [Abstract][Full Text] [Related]
8. ROC analysis of selected matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in psoriatic patients.
Glazewska EK; Niczyporuk M; Lawicki S; Szmitkowski M; Zajkowska M; Donejko M; Przylipiak A
Postepy Dermatol Alergol; 2018 Apr; 35(2):167-173. PubMed ID: 29760617
[TBL] [Abstract][Full Text] [Related]
9. Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression.
Gurbel PA; Kreutz RP; Bliden KP; DiChiara J; Tantry US
Am Heart J; 2008 Jan; 155(1):56-61. PubMed ID: 18082490
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase-3 predicts clinical cardiovascular outcomes in patients with coronary artery disease: a 5 years cohort study.
Guizani I; Zidi W; Zayani Y; Boudiche S; Hadj-Taieb S; Sanhaji H; Zaroui A; Mechmeche R; Mourali MS; Feki M; Allal-Elasmi M
Mol Biol Rep; 2019 Oct; 46(5):4699-4707. PubMed ID: 31218540
[TBL] [Abstract][Full Text] [Related]
11. Interferon-gamma increases the ratio of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 in peripheral monocytes from patients with coronary artery disease.
Springall R; Amezcua-Guerra LM; Gonzalez-Pacheco H; Furuzawa-Carballeda J; Gomez-Garcia L; Marquez-Velasco R; Mejía-Domínguez AM; Cossío-Aranda J; Martínez-Sánchez C; Bojalil R
PLoS One; 2013; 8(8):e72291. PubMed ID: 23951304
[TBL] [Abstract][Full Text] [Related]
12. Does Arterial Hypertension Affect Plasma Levels of Matrix Metalloproteinases and Their Tissue Inhibitors in Patients with Stable Coronary Artery Disease? A Preliminary Study.
Kuliczkowski W; Banaszkiewicz M; Mysiak A; Makaś G; Bil-Lula I
Cardiol Res Pract; 2019; 2019():6921315. PubMed ID: 31781384
[TBL] [Abstract][Full Text] [Related]
13. Granulocytes in coronary thrombus evolution after myocardial infarction--time-dependent changes in expression of matrix metalloproteinases.
Li X; de Boer OJ; Ploegmaker H; Teeling P; Daemen MJ; de Winter RJ; van der Wal AC
Cardiovasc Pathol; 2016; 25(1):40-6. PubMed ID: 26490693
[TBL] [Abstract][Full Text] [Related]
14. Increased Incidence of Ischemic Cerebrovascular Events in Cardiovascular Patients With Elevated Apolipoprotein CIII.
Olivieri O; Cappellari M; Turcato G; Bonetti B; Girelli D; Pizzolo F; Friso S; Bassi A; Castagna A; Martinelli N
Stroke; 2020 Jan; 51(1):61-68. PubMed ID: 31795904
[TBL] [Abstract][Full Text] [Related]
15. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
Brunner S; Kim JO; Methe H
Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
[TBL] [Abstract][Full Text] [Related]
17. Role of matrix metalloproteinases in coronary artery disease.
Shah VK; Shalia KK; Mashru MR; Soneji SL; Abraham A; Kudalkar KV; Vasvani JB; Sanghavi ST
Indian Heart J; 2009; 61(1):44-50. PubMed ID: 19729688
[TBL] [Abstract][Full Text] [Related]
18. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis.
Noji Y; Kajinami K; Kawashiri MA; Todo Y; Horita T; Nohara A; Higashikata T; Inazu A; Koizumi J; Takegoshi T; Mabuchi H
Clin Chem Lab Med; 2001 May; 39(5):380-4. PubMed ID: 11434385
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases and inflammatory markers in coronary artery ectasia: their relationship to severity of coronary artery ectasia.
Dogan A; Tuzun N; Turker Y; Akcay S; Kaya S; Ozaydin M
Coron Artery Dis; 2008 Dec; 19(8):559-63. PubMed ID: 19005290
[TBL] [Abstract][Full Text] [Related]
20. Association of plasma free fatty acids levels with the presence and severity of coronary and carotid atherosclerotic plaque in patients with type 2 diabetes mellitus.
Zhang MH; Cao YX; Wu LG; Guo N; Hou BJ; Sun LJ; Guo YL; Wu NQ; Dong Q; Li JJ
BMC Endocr Disord; 2020 Oct; 20(1):156. PubMed ID: 33087077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
